ABUS
Arbutus Biopharma Corp

16,875
Loading...
Loading...
News
all
press releases
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·17d ago
News Placeholder
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks·5mo ago
News Placeholder
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks·5mo ago
News Placeholder
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Zacks·5mo ago
News Placeholder
Cramer+apos;s Lightning Round: Arbutus Biopharma is +apos;the ultimate spec+apos;
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer·9mo ago
News Placeholder
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Whitefort Capital Management, LP (together with its affiliates, Whitefort Capital, us or we), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ...
Business Wire·1y ago

Latest ABUS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.